stoxline Quote Chart Rank Option Currency Glossary
  
Lantheus Holdings, Inc. (LNTH)
81.18  -1.45 (-1.75%)    06-18 12:04
Open: 82.31
High: 82.989
Volume: 203,552
  
Pre. Close: 82.63
Low: 80.48
Market Cap: 5,627(M)
Technical analysis
2024-06-18 11:51:40 AM
Short term     
Mid term     
Targets 6-month :  98.36 1-year :  114.88
Resists First :  84.21 Second :  98.36
Pivot price 80.95
Supports First :  79.81 Second :  77.09
MAs MA(5) :  80.64 MA(20) :  80.65
MA(100) :  66.64 MA(250) :  68.53
MACD MACD :  1.6 Signal :  2.1
%K %D K(14,3) :  51.5 D(3) :  47.1
RSI RSI(14): 55.5
52-week High :  94.01 Low :  50.2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LNTH ] has closed above bottom band by 47.0%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 83.03 - 83.53 83.53 - 84.01
Low: 77.72 - 78.29 78.29 - 78.84
Close: 81.72 - 82.59 82.59 - 83.43
Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Headline News

Tue, 18 Jun 2024
Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens Sells 341 Shares - Defense World

Mon, 17 Jun 2024
Andrea Sabens Sells 341 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock - MarketBeat

Mon, 17 Jun 2024
Greenwood Capital Associates LLC Purchases New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) - Defense World

Sat, 15 Jun 2024
Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Holdings Cut by Osterweis Capital Management Inc. - Defense World

Sat, 15 Jun 2024
Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Osterweis Capital Management Inc. - MarketBeat

Mon, 10 Jun 2024
Lantheus Holdings (LNTH) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 69 (M)
Shares Float 68 (M)
Held by Insiders 2.5 (%)
Held by Institutions 100.1 (%)
Shares Short 4,480 (K)
Shares Short P.Month 4,650 (K)
Stock Financials
EPS 6.55
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 13.64
Profit Margin 33.7 %
Operating Margin 27.1 %
Return on Assets (ttm) 19 %
Return on Equity (ttm) 66.2 %
Qtrly Rev. Growth 23 %
Gross Profit (p.s.) 0
Sales Per Share 19.76
EBITDA (p.s.) 7.85
Qtrly Earnings Growth 0 %
Operating Cash Flow 324 (M)
Levered Free Cash Flow 188 (M)
Stock Valuations
PE Ratio 12.31
PEG Ratio 0.3
Price to Book value 5.92
Price to Sales 4.08
Price to Cash Flow 17.28
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android